Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository
Author:
Funder
U.S. Department of Defense
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40801-023-00360-8.pdf
Reference23 articles.
1. Bavendiek U, Berliner D, Dávila LA, Schwab J, Maier L, Philipp SA, et al. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur J Heart Fail. 2019;21(5):676–84. https://doi.org/10.1002/ejhf.1452.
2. Konstantinou DM, Karvounis H, Giannakoulas G. Digoxin in heart failure with a reduced ejection fraction: a risk factor or a risk marker. Cardiology. 2016;134(3):311–9. https://doi.org/10.1159/000444078.
3. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA. 2020;324(24):2497–508. https://doi.org/10.1001/jama.2020.23138.
4. Pervaiz MH, Dickinson MG, Yamani M. Is digoxin a drug of the past? Cleve Clin J Med. 2006;73(9):821–4. https://doi.org/10.3949/ccjm.73.9.821. (6, 9–32 passim).
5. Rosca CI, Kundnani NR, Tudor A, Rosca MS, Nicoras VA, Otiman G, et al. Benefits of prescribing low-dose digoxin in atrial fibrillation. Int J Immunopathol Pharmacol. 2021. https://doi.org/10.1177/20587384211051955.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Inflammation in the COVID-19 airway is due to inhibition of CFTR signaling by the SARS-CoV-2 spike protein;Scientific Reports;2024-07-23
2. “Cardiac glycosides”—quo vaditis?—past, present, and future?;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-15
3. Decision making performance of business analytics capabilities: the role of big data literacy and analytics competency;Business Process Management Journal;2024-07-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3